Skip to search formSkip to main contentSkip to account menu

RoActemra®

Known as: RoActemra 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Inhibition du récepteur de l’interleukine-6 au cours du syndrome de Gougerot-Sjögren primaire : essai randomisé multicentrique académique en double aveugle tocilizumab versus placebo (ETAP study)
2019
2019
Tocilizumab (Actemra, RoActemra)
Tocilizumab (Actemra) is a drug used to treat autoimmune diseases, including rheumatoid arthritis, through a novel mechanism of… 
2019
2019
RoActemra (Tocilizumab): riesgo de daño hepático grave
2019
2019
RoActemra® (tocilizumab): Riesgo (poco frecuente) de daño hepático grave incluyendo fallo hepático agudo que requiere trasplante
2018
2018
Akne-Triade als paradoxe Reaktion auf Therapie mit dem IL-6-Inhibitor Tocilizumab
Zusammenfassung Als Akne-Triade bezeichnet man eine Kombination aus Acne conglobata und intertriginöser Akne axillär (sog… 
2017
2017
Une dacryoadénite « Stillée »
Review
2014
Review
2014
Biological Therapeutics and Pharmacovigilance in Italy
Biological Therapeutics (BTs) present a novel frontier for the treatment of autoimmune diseases, such as rheumatoid arthritis… 
2014
2014
FRI0300 Baseline Characteristics and Pattern of TOCILIZUMAB Use in Patients with Rheumatoid Arthritis: Interim Results from the Multinational, Observational ACT-UP Study
Background Tocilizumab (TCZ), an IL-6 receptor inhibitor, has been approved in combination with disease-modifying antirheumatic… 
2014
2014
R040/14 Angående RoACTEMRA information om ny app Avskrivet enl. p. 16
2010
2010
Tocilizumab in Rheumatoid Arthritis
Correspondence to: Amy Ka-Man Yung Abstract: Rheumatoid arthritis is a chronic debilitating disease. Nowadays, rheumatologists… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)